Dopo l'orario di chiusura: 1.53 0.01 +0.66%

Atossa Therapeutics Inc (ATOS)

Atossa Therapeutics Inc Borsa (ATOS) Ultime notizie

Atossa Therapeutics Inc (ATOS)

Atossa Therapeutics Inc Borsa (ATOS) Ultime notizie

Rhumbline Advisers Makes New $161,000 Investment in Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World

Was Atossa Therapeutics Inc (ATOS)’s session last reading good? - US Post News

Atossa Therapeutics, Inc. (NASDAQ:ATOS) Shares Acquired by Bank of New York Mellon Corp - MarketBeat

Atossa Therapeutics, Inc. (NASDAQ:ATOS) Shares Acquired by Bank of New York Mellon Corp - Defense World

Atossa Therapeutics Inc [ATOS] Investment Guide: What You Need to Know - Knox Daily

What Has Been Going On With Atossa Therapeutics Inc (NASDAQ: ATOS) - Stocks Register

Atossa Therapeutics Inc (ATOS) can make a big difference with a little luck - SETE News

Atossa Therapeutics (NASDAQ:ATOS) Shares Pass Above Two Hundred Day Moving Average of $1.41 - MarketBeat

Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance

What is the investor’s view on Atossa Therapeutics Inc (ATOS)? - US Post News

Potential Price Increase for Atossa Therapeutics Inc (ATOS) After Recent Insider Activity - Knox Daily

Ratios Reveal: Breaking Down Atossa Therapeutics Inc (ATOS)’s Financial Health - The Dwinnex

Atossa Therapeutics Inc: Weathering Stock Market Storms with 182.35M Market Cap - The InvestChronicle

Taking on analysts’ expectations and winning: Atossa Therapeutics Inc (ATOS) - SETE News

Examining Atossa Therapeutics Inc (ATOS) stock is warranted - US Post News

Atossa Therapeutics (NASDAQ:ATOS) Price Target Increased to $6.50 by Analysts at Ascendiant Capital Markets - Defense World

Analyzing Atossa Therapeutics Inc (ATOS) After Recent Trading Activity - Knox Daily

Atossa Therapeutics (NASDAQ:ATOS) Price Target Raised to $6.50 - MarketBeat

Atossa Therapeutics Inc’s Shares Reel: 21.67% Quarterly Revenue Decline Amid 183.61M Market Cap - The InvestChronicle

Atossa Therapeutics Announces Support of Final Rule from FDA Requiring Patient Notification of Breast Density, a Critical Step in Addressing a Known Risk Factor for Breast Cancer - StockTitan

Atossa Therapeutics (NASDAQ:ATOS) Share Price Passes Below 200-Day Moving Average of $1.38 - MarketBeat

Are Atossa Therapeutics Inc (ATOS) shares a good deal now? - US Post News

Is Atossa Genetics (ATOS) Outperforming Other Medical Stocks This Year? - Yahoo Finance

Atossa Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference - StockTitan

Recent Insider Activity Suggests Potential Gains for Atossa Therapeutics Inc (ATOS) - Knox Daily

Are You Looking for a Top Momentum Pick? Why Atossa Genetics Inc. (ATOS) is a Great Choice - Yahoo Finance

Dow Jones Industrials Average (DOWI) QuotePress Release - The Globe and Mail

TSX Materials Capped Index (TTMT) QuotePress Release - The Globe and Mail

Atossa Therapeutics Inc (ATOS-Q) QuotePress Release - The Globe and Mail

Atossa secures new patent for breast cancer drug By Investing.com - Investing.com Canada

Atossa secures new patent for breast cancer drug - Investing.com

Nothing is Better Than Atossa Therapeutics Inc (ATOS) stock at the moment - SETE News

Atossa secures new patent for breast cancer drug By Investing.com - Investing.com UK

Atossa Therapeutics Granted Additional Patent Protection for Endoxifen - Yahoo Canada Finance

Atossa Therapeutics Inc (ATOS) Stock: A Comprehensive 52-Week Review - The InvestChronicle

TSX Utilities Capped Index (TTUT) QuotePress Release - The Globe and Mail

Can you now get a good deal on Atossa Therapeutics Inc’s shares? - US Post News

The Potential Rise in the Price of Atossa Therapeutics Inc (ATOS) following insiders activity - Knox Daily

Financial Comparison: Atossa Therapeutics (NASDAQ:ATOS) versus Renovaro (NASDAQ:RENB) - Defense World

When Can We Expect A Profit From Atossa Therapeutics, Inc. (NASDAQ:ATOS)? - Simply Wall St

Atossa and Quantum Leap begin breast cancer treatment trial - Investing.com India

Understanding the Risks of Investing in Atossa Therapeutics Inc (ATOS) - Knox Daily

Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Combining (Z)-Endoxifen with Abemaciclib for ER+/HER2- Breast Cancer - ForexTV.com

Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Combining (Z)-Endoxifen with Abemaciclib for ER+/HER2- Breast Cancer - Yahoo Finance

Atossa and Quantum Leap begin breast cancer treatment trial By Investing.com - Investing.com Australia

Atossa and Quantum Leap begin breast cancer treatment trial - Investing.com

Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Combining (Z)-Endoxifen with Abemaciclib for ER+/HER2- Breast Cancer - StockTitan

Atossa Therapeutics Announces the Appointment of Michael Parks as Vice President, Investor and Public Relations - StockTitan

Cetera Advisors LLC Takes $72,000 Position in Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World

FY2024 Earnings Estimate for Atossa Therapeutics, Inc. (NASDAQ:ATOS) Issued By Cantor Fitzgerald - Defense World

FY2024 EPS Estimates for Atossa Therapeutics, Inc. Lifted by Analyst (NASDAQ:ATOS) - MarketBeat

Equities Analysts Set Expectations for Atossa Therapeutics, Inc.’s Q3 2024 Earnings (NASDAQ:ATOS) - Defense World

Atossa Therapeutics (NASDAQ:ATOS) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPS - Defense World

Atossa Therapeutics (NASDAQ:ATOS) Downgraded to Sell at StockNews.com - Defense World

Atossa Therapeutics (NASDAQ:ATOS) Issues Quarterly Earnings Results - MarketBeat

Atossa Therapeutics (NASDAQ:ATOS) Receives Buy Rating from HC Wainwright - Defense World

Atossa Therapeutics (NASDAQ:ATOS) Cut to "Sell" at StockNews.com - MarketBeat

Atossa Therapeutics' (ATOS) "Buy" Rating Reiterated at HC Wainwright - MarketBeat

ATOS Stock Earnings: Atossa Therapeutics Beats EPS for Q2 2024 - InvestorPlace

Atossa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire

Atossa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update - StockTitan

Here's Why We're Not Too Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Situation - Yahoo Finance

83,941 Shares in Atossa Therapeutics, Inc. (NASDAQ:ATOS) Bought by Virtu Financial LLC - Defense World

How to interpret Atossa Therapeutics Inc (ATOS)’s stock chart patterns - US Post News

Simile a ATOS